Education
About Us
Working with TipRanks
Follow Us
Assertio Therapeutics Inc (ASRT)
NASDAQ:ASRT
Earnings Data
Report Date
May 11, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-1.86Last Year’s EPS
-2.1Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a constructive long-term outlook centered on Robodon: integration is complete, FY2025 results beat guidance, margins and adjusted EBITDA improved year-over-year, and management provided 2026 guidance that anticipates profitability expansion. However, material near-term challenges remain — notably the large Q4 revenue decline and negative Q4 adjusted EBITDA driven by a timing-driven sell-in, a significant sequential cash reduction due to working capital, and ongoing erosion risk in legacy products (Indocin) from generic competition. Management frames many negatives as temporary (sell-in timing, working capital) and emphasizes durable improvements (commercial platform, cost reductions, Robodon secular demand). Balancing the substantial positive catalysts and guidance against the short-term execution and cash pressures yields an overall positive outlook conditional on Robodon demand and normalization of working capital.Company Guidance
Robodon Integration Completed and Positioned for Growth
Integration of Robodon onto Assertio's label and commercial platform completed in Q4 2025; transition included a deliberate pull-forward of two quarters of demand to ensure uninterrupted patient supply. Regular sales of newly labeled Robodon expected to begin in Q2 2026. Management cites underlying demand growth for Robodon of ~32% year-over-year in 2025 and views the product as long-term core asset (IP protection through 2039) with potential to exceed $100M–$130M peak annual U.S. sales.
Full-Year 2025 Results Above Guidance
Total product sales for FY2025 were $117.1M, above the high end of updated guidance. Rovodon FY sales were $68.2M, up from $60.1M (+13.5% YoY). Full-year adjusted EBITDA improved to $22.7M from $18.3M (+24.0% YoY). Gross margin improved to 70% for FY2025 (vs. 68% in FY2024).
Significant Margin and Cost Improvements
Q4 gross margin increased to 75% from 61% in the prior-year quarter (+14 percentage points), driven by a higher mix of Indocin sales and non-recurrence of prior-year inventory write-downs. Reported SG&A in Q4 was $13.1M, down from $21.4M (-38.8% YoY), reflecting lower legal expenses and restructuring actions. Management expects structural cost savings (litigation, decommercialization, leaner personnel) and estimates a 2026 SG&A reduction of approximately $3M–$5M YoY.
2026 Financial Guidance Reflects Profitability Upside
Fiscal 2026 guidance: revenue $110M–$125M and adjusted EBITDA $28M–$40M, implying year-over-year margin expansion driven by high-margin Robodon growth and existing commercial capacity to capture additional volume without proportional OpEx increases.
Scalable Commercial Infrastructure for Oncology
Company has a national field team, national accounts/GPO contracting capability, strong distributor/GPO relationships, and an integrated patient services hub. Management believes this platform can be leveraged to commercialize therapeutics (late-stage/on-market) in community oncology with only small incremental investments to sales/marketing.
Working Capital Normalization Plan
Cash, cash equivalents and short-term investments were $63.4M as of 12/31/2025, down from $93.4M at 9/30/2025 (-32.1%), driven primarily by temporary working capital increases (AR expansion, accrued rebates) related to the Rovodon sell-in. Management expects working capital and cash flows to normalize by April 2026 as channel inventory pulls through.
ASRT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ASRT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 16, 2026 | $11.77 | $12.50 | +6.20% |
Nov 10, 2025 | $12.02 | $13.80 | +14.81% |
Aug 11, 2025 | $10.88 | $12.38 | +13.79% |
May 12, 2025 | $9.23 | $9.13 | -1.08% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Assertio Therapeutics Inc (ASRT) report earnings?
Assertio Therapeutics Inc (ASRT) is schdueled to report earning on May 11, 2026, Before Open (Confirmed).
What is Assertio Therapeutics Inc (ASRT) earnings time?
Assertio Therapeutics Inc (ASRT) earnings time is at May 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ASRT EPS forecast?
ASRT EPS forecast for the fiscal quarter 2026 (Q1) is -1.86.